The abstract is read at the publisher; the summary is JClub's.
E2F1 is overexpressed in neuroendocrine prostate cancer tumors and is linked to poor prognosis, with E2F1 driving NEPC-associated transcriptional programs in prostate adenocarcinoma cells.
- Why it matters: NEPC is linked to resistance against anti-androgen receptor therapy, yet how E2F1 contributes beyond its canonical RB1–cell cycle control is unclear.
- What they did: The study assessed patient NEPC tumors for E2F1 expression and prognosis, then tested prostate adenocarcinoma cells for NEPC-like transcription, stemness, and INSM1 induction, using E2F1 depletion and FOXA2 co-localization at regulatory elements.
- The result: E2F1 overexpression increases stemness and induces INSM1 in advanced prostate cancer, while E2F1 depletion reduces stemness and enhances neural lineage gene expression, implying E2F1 drives NEPC programs via REST de-repression and altered FOXA2/ASCL1 DNA binding.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.